Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Clonal hematopoiesis dynamics influences long-term outcomes of follicular lymphoma: Results from FIL FOLL12 trial.

HemaSphere·2026

Same author

B-cell and plasma cell proliferations associated with T follicular helper cell lymphomas: clinical-pathological and genetic features.

Virchows Archiv : an international journal of pathology·2026

Same author

The normal human lymph node cell classification and landscape defined by high-dimensional spatial proteomics.

PloS one·2026

Same author

Mediastinal grey zone lymphomas: Results of the expert pathological review analysis of a case series enrolled in the multicentre BIOGZL-2020 study in Italy.

British journal of haematology·2026

Same author

Joint Assessment of CD38, CD138, and Immunoglobulin Light Chains Supports the Differential Diagnosis Between Classical Hodgkin Lymphoma and Plasmablastic Lymphoma.

International journal of laboratory hematology·2026

Same author

RAG1/2 expression in IGH-switched follicular lymphoma associated with transformation to high-grade B-cell lymphoma.

Leukemia·2026

Same journal

Breast carcinoma metastasizing to an adrenocortical adenoma: a case of tumour-to-tumour metastasis.

Pathologica·2026

Same journal

Metastatic melanoma with heterologous bone after neoadjuvant immunotherapy: diagnostic insights.

Pathologica·2026

Same journal

Lymphangitic breast cancer in explanted lungs with interstitial lung disease: an unexpected finding.

Pathologica·2026

Same journal

Histological insights into sudden, unexpected death due to tuberculosis: two autopsy case reports and review of the literature.

Pathologica·2026

Same journal

Teaching with human remains: curatorship, technological innovation and ethical engagement at the Morgagni Museum of Human Anatomy.

Pathologica·2026

Same journal

Technical feasibility of a long read, fourth generation sequencing platform in diagnostic profiling of clinical routine samples: a proof-of-concept study.

Pathologica·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Oct 11, 2025

Generation of a Novel Dendritic-cell Vaccine Using Melanoma and Squamous Cancer Stem Cells

Generation of a Novel Dendritic-cell Vaccine Using Melanoma and Squamous Cancer Stem Cells

Published on: January 6, 2014

Follicular dendritic cell sarcoma.

Fabio Facchetti¹, Matteo Simbeni¹, Luisa Lorenzi¹

¹Department of Molecular and Translational Medicine, Section of Pathology, University of Brescia, Spedali Civili, Brescia (Italy).

|November 27, 2021

Summary

This summary is machine-generated.

Follicular dendritic cell sarcoma (FDCS) is a rare tumor that can mimic other conditions. Diagnosis requires specific markers, and while surgery is standard, new molecular insights may offer future therapeutic strategies.

Keywords:

diagnosis follicular dendritic cell sarcoma mutations personalized medicine

More Related Videos

Isolation and Characterization of Tumor-initiating Cells from Sarcoma Patient-derived Xenografts

Isolation and Characterization of Tumor-initiating Cells from Sarcoma Patient-derived Xenografts

Published on: June 13, 2019

Isolation And Dendritic Cell-Uptake of Small Extracellular Vesicles from Echinococcus granulosus

Isolation And Dendritic Cell-Uptake of Small Extracellular Vesicles from Echinococcus granulosus

Published on: March 28, 2025

Related Experiment Videos

Last Updated: Oct 11, 2025

Generation of a Novel Dendritic-cell Vaccine Using Melanoma and Squamous Cancer Stem Cells

Generation of a Novel Dendritic-cell Vaccine Using Melanoma and Squamous Cancer Stem Cells

Published on: January 6, 2014

Isolation and Characterization of Tumor-initiating Cells from Sarcoma Patient-derived Xenografts

Isolation and Characterization of Tumor-initiating Cells from Sarcoma Patient-derived Xenografts

Published on: June 13, 2019

Isolation And Dendritic Cell-Uptake of Small Extracellular Vesicles from Echinococcus granulosus

Isolation And Dendritic Cell-Uptake of Small Extracellular Vesicles from Echinococcus granulosus

Published on: March 28, 2025

Area of Science:

Immunology
Oncology
Pathology

Background:

Follicular dendritic cells (FDCs) are crucial for B-cell adaptive immunity.
Follicular Dendritic Cell Sarcoma (FDCS) was first described in 1986, exhibiting heterogeneous microscopic, immunohistochemical, and ultrastructural features.
FDCS predominantly occurs in extranodal sites and lymph nodes, sometimes associated with Castleman disease.

Purpose of the Study:

To review the key features of Follicular Dendritic Cell Sarcoma (FDCS).
To highlight diagnostic challenges and criteria for FDCS.
To discuss current understanding of FDCS genetics, behavior, and treatment.

Main Methods:

Review of literature on Follicular Dendritic Cell Sarcoma (FDCS).
Analysis of histopathological, immunohistochemical, and molecular findings.
Evaluation of clinical presentation, behavior, and treatment outcomes.

Main Results:

FDCS presents diagnostic challenges due to variable morphology and potential antigen loss, necessitating a broad panel of FDC markers.
The inflammatory-pseudotumor-like (IPT-like) variant is characterized by Epstein-Barr virus positivity.
While lacking specific genetic anomalies, FDCS often shows aberrant karyotypes and alterations in NF-κB and cell-cycle regulatory pathways.
Recurrence (28%) and metastasis (27%) are significant concerns, influenced by disease extent and resectability.

Conclusions:

Accurate diagnosis of FDCS relies on comprehensive immunohistochemical analysis.
Understanding the molecular landscape of FDCS is critical for developing novel therapeutic strategies.
Complete surgical excision remains the primary treatment, with limited data on targeted or immunotherapies.